The FDA approved the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations called EGFR exon 20 insertion mutations.
Read more: FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer